Table 4 Evolution of concomitant treatment and interventions during the study period ^a

Baseline

Vasopressors

9

9

Vasopressor dose (μg/kg/min)

0.04 ± 0.06

0.07 ± 0.1

Levosimendan (0.1 μg/kg/min)

5

4

Dobutamine

1

0

IABP

2

4

Invasive ventilation

10

14

Noninvasive ventilation

5

1

24 hours

Vasopressors

7

3

Vasopressor dose (μg/kg/min)

0.03 ± 0.05

0.03 ± 0.1

IABP

2

4

Invasive ventilation

9

10

Noninvasive ventilation

5

0

48 hours

Vasopressors

2

3

Vasopressor dose (μg/kg/min)

0.01 ± 0.03

0.04 ± 0.1

IABP

2

3

Invasive ventilation

4

9

Noninvasive ventilation

1

2